Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Intra-patient Randomised Controlled Phase III Study to Confirm the Efficacy and Safety of denovoSkin™, a Bilayer Engineered Collagen-based Skin Graft Composed of Autologous Fibroblasts and Keratinocytes, for the Treatment of Patients With Deep Partial and Full-thickness Burns

NCT06745557 is registered in ClinicalTrials.gov with CUTISS AG as lead sponsor.

NCT NCT06745557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06745557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Intra-patient Randomised Controlled Phase III Study to Confirm the Efficacy and Safety of denovoSkin™, a Bilayer Engineered Collagen-based Skin Graft Composed of Autologous Fibroblasts and Keratinocytes, for the Treatment of Patients With Deep Partial and Full-thickness Burns
Lead sponsor
CUTISS AG
Phase
Phase 3
Overall status
Recruiting
Start date
December 13, 2024
Completion date
June 30, 2029
Enrollment
70 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

burns